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Low bone turnover in patients with renal failure. Renal failure can be encountered, a summary of which is presented
inevitably leads to metabolic bone disease. Low turnover dis- in Fig. 1. In most cases, the definite diagnosis of the type
ease or adynamic bone disease (ABD) is characterized by a of ROD still must rely on the histomorphometric analysislow number of osteoblasts with normal or reduced numbers
of a bone biopsy [1, 2]. If the biopsy is performed afterof osteoclasts. Mineralization proceeds at a normal rate, re-
double tetracycline labeling, the bone formation ratesulting in normal or decreased osteoid thickness. Recently, it
became clear that the relative contribution of the various types (BFR) can be calculated by multiplying the mineral op-
of renal osteodystrophy (ROD) to the spectrum of the histo- position rate by the extent of the labeled surfaces [3].
logic picture in renal failure patients underwent profound Low bone turnover leads to two distinct types of ROD:changes during the last 25 years. At the moment, the exact
adynamic bone disease and osteomalacia.physiopathological mechanisms behind ABD are not yet eluci-
dated, and thus the reason(s) for its increasing prevalence re-
mains poorly understood. A number of epidemiological and
ADYNAMIC BONE DISEASEexperimental data suggest a multifactorial pathophysiologic
process, in which hypoparathyroidism and suppression of the The first type of low turnover disease, adynamic bone
osteoblast are the main actors. Compared to adynamic bone disease (ABD), is characterized by a low number ofdisease, osteomalacia has now become a much rarer disease
osteoblasts, the osteoclast number usually being normal(around 4%), at least in Western countries. On the other hand,
or reduced. Mineralization proceeds at a normal rate,recent studies indicate that this particular bone disease entity
might still regularly occur in less developed countries. Osteo- resulting in normal or decreased osteoid thickness [3].
malacia originates from a direct effect on the mineralization Recently, it became clear that the relative contribution
process. With this type of renal bone disease, the effects of
of the various types of ROD to the spectrum of thesecondary hyperparathyroidism on bone are overridden by a
histologic picture in renal failure patients underwent pro-number of metabolic abnormalities that finally result in a defec-
tive bone mineralization, as occurs, for instance, when the found changes over the last 25 years. A summary of the
lag time between osteoid deposition and its mineralization is literature data on biopsy proven prevalence rates of the
increased. The relationship between exogenous and endoge- different types of ROD reported over the years is pre-
nous vitamin D deficiency (mainly calcitriol) and the histologic
sented in Table 1 [4–16].finding of osteomalacia in uremic patients is well known. Re-
Before 1989, ABD was either not encountered or hadcent data showed distinctly lowered 25-(OH) vitamin D3 levels
in the presence of unaffected calcitriol concentrations in patients a very low prevalence. In the following years, a clear
with osteomalacic lesions, as assessed radiologically by the pres- increase in its prevalence was recorded predialysis (even
ence of Looser’s zones. Recently, we found that bone strontium at relatively low levels of renal failure) in hemodialysislevels were increased in patients with osteomalacia as compared
as well as in continuous ambulatory peritoneal dialysisto all other types of ROD. Strontium accumulation appeared
to originate mainly from the use of strontium-contaminated dial- (CAPD) patients. At present, in CAPD patients it even
ysate, which resulted from the addition of strontium-containing appears to be the most frequently encountered disease
acetate-based concentrates. Evidence for a causal role of the entity [11, 14]. More recently, we could confirm this highelement in the development of a mineralization defect could
prevalence in a wide sample of the European CAPDbe tested experimentally by adding strontium to drinking water
population [17]. This increasing prevalence seems to oc-in a chronic renal failure rat model.
cur at the expense of both hyperparathyroid bone lesions
and osteomalacia, ruling out that changing the criteria
Renal failure inevitably leads to metabolic bone disease. for the definition of OM might account for this evolution
Depending on the metabolic factor(s) with the greatest as has been suggested in literature. The low numbers
impact, several types of renal osteodystrophy (ROD) reported by some authors after 1989 can be attributed
to either methodological [9, 16] or selection [15] biases.
At the moment, the exact physiopathological mecha-Key words: adynamic bone disease, osteomalacia, renal osteodystro-
phy, strontium, vitamin D. nisms behind ABD are not yet elucidated, and thus the
reason(s) for its increasing prevalence remain(s) poorly 1999 by the International Society of Nephrology
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Recent data on the influence of the vitamin D receptor
gene polymorphism on the level of PTH in hemodialyzed
patients remain to be confirmed, but they point towards
genetic heterogeneity playing a role in determining the
functioning of the parathyroids in renal failure patients
[23]. On the other hand, many chronic renal failure re-
lated factors play a role in the expression of the vitamin D
receptor at the level of the parathyroid cell, such as
calcemia, phosphatemia, PTH itself, and uremic toxins
[24]. A change in the expression of the calcium receptor
can be hypothesized to play a role in the parathyroid
function. The important regulatory effect of phosphatemia
on PTH synthesis and secretion through direct interac-
tion with the parathyroid cell has been demonstratedFig. 1. Histologic classification of renal osteodystrophy (BFR 5 bone
[25]. The role, if any, of a better control of phosphatemiaformation rate).
in renal failure patients with ABD remains to be defined.
Diabetes, a risk factor for ABD, has also been shown
to be associated with hypofunctioning parathyroid glandsunderstood. However, a number of epidemiological and
experimental data suggest a multifactorial pathophysio- [26]. Long-term chronic hypermagnesemia has also been
described to be associated with low PTH levels [27].logic process, which we tried to summarize in Fig. 2.
Finally, older age as well as malnourishment have been
Hypoparathyroidism associated with reduced PTH levels [28].
Obviously, a high calcium level by itself remains theEpidemiological studies have revealed an association
of ABD with a “relative” hypoparathyroidism, i.e., para- main suppressor of the parathyroid cell. Epidemiologic
studies have indeed pointed out that chronic intake ofthyroid hormone (PTH) levels that are significantly
lower than those noted in renal failure patients present- CaCO3 as a phosphate binder [10, 11, 29] as well as
treatment by peritoneal dialysis with its higher calciuming with other types of ROD, but still higher than in
subjects with normal renal function [9, 11–13, 16]. mass transfer as compared to hemodialysis [30] are risk
factors for ABD. In this respect the finding of HutchisonMeanwhile, it has been demonstrated that the parathy-
roid glands in ABD patients respond to changes in ion- et al [12] of higher ionized calcium levels in ABD than
in patients with other types of ROD is highly relevant.ized calcium levels in a way comparable to the response
in subjects with normal renal function [18, 19], raising the The question why ABD patients present with a ten-
dency to hypercalcemia has been addressed by Kurz etquestion of why the parathyroid glands in these patients
function at a more suppressed level. Different factors al [31] who showed by calcium kinetic studies that ABD
results in a lower capacity of the bone to buffer calciumhave been described as associated with an increased risk
for ABD; some of these are known to down-regulate and to handle extra calcium loads (such as CaCO3). This
fits in with the decreased activity of the osteoblast asthe parathyroid function, as outlined in Fig. 2. In the
past, aluminum certainly played a role in suppressing expressed by the decreased bone formation rate ob-
served in bone biopsies of ABD patients.PTH secretion [20], but in an era where aluminum expo-
sure is minimal, relative iron deficiency being frequently
Osteoblast suppressionobserved in erythropoietin treatment and inducing a con-
comitant up-regulation of transferrin receptors, might Defective osteoblast functioning in ABD patients was
shown indirectly by Marie et al [32] to be reflected infacilitate the uptake of aluminum even at very low levels
of this element [21]. vitro by a clear reduction of DNA replication of osteo-
blastic cells recovered from ABD patients as comparedVitamin D has since long been shown to reduce PTH
synthesis and is widely used for secondary hyperparathy- to normal subjects. This decreased bone formation oc-
curs despite levels of PTH higher than in normal subjects,roidism both in prophylaxis and as a therapeutic agent.
Although in large epidemiological studies, vitamin D suggesting that the bone of these patients is hyporeactive
or “resistant” to the stimulatory effect of PTH. A down-could never be retained as a significant risk factor for
ABD [10, 11, 17] its contribution to the generation of regulation of the PTH-PTHrP-receptor on the osteo-
blasts [22] of uremic patients would fit in perfectly withhypoparathyroidism and ABD has been documented in
individual patients [9]. In addition, active vitamin D me- this line of thought, but it remains to be proven. The
finding of reduced PTH receptor mRNA in epiphysialtabolites down-regulate PTH receptors in osteoblastic
cells, and subsequently the action of PTH on bone re- cartilage growth plate in uremic rats [33] is highly sugges-
tive in this context. On the other hand, osteoblastic pro-modeling [22].
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Table 1. Summary of published prevalences (%) of different types of ROD over the years
Author (et al.), year (Ref.) Type of patients OF MX NL* OM ABD
Sherrard, 1972 (5) HD 67 9 – 24 0
Llach, 1986 (6) HD 68† – 25 7
Salusky, 1988 (4) CAPD (children) 64 0 16 9 11
Morinie`re, 1989 (7) HD 76† – 0 24
Hutchison, 1991 (8) ESRD 53 9 – 22 16
Cohen-Solal, 1992 (9) ESRD 37 10 33 11 0
Malluche, 1992 (10) HD1CAPD a) 1984 27 53 – 15 5
b) 1991 22 56 – 2 20
Sherrard, 1993 (11) HD 50 11 – 3 36
CAPD 50 4 – 6 61
Hutchison, 1993 (12) ESRD 50 13 – 7 27
Hernandez, 1994 (13) ESRD 56† – 11 33
Torres, 1995 (14) ESRD 40 10 – 2 48
HD 44 12 – 12 32
CAPD 32 10 – 10 48
Hamdy, 1995 (15) CRF 73 19 25 1 5
Coen, 1996 (16) CRF 69† 13 9 12
* Some authors do not include “normals” in the differential diagnosis of ROD.
† In these studies, OF and MX are taken together.
Fig. 2. Physiopathology of adynamic bone: A
hypothesis (P 5 phosphorus, VDR 5 vitamin D
receptor, BFR 5 bone formation rate).
liferation and function can be down-regulated by factors of uremic toxins for the osteoblasts, which are gradually
removed by dialysis, might play a role as proposed byindependent of PTH interaction, many of which have
been described in epidemiological studies as indepen- Andress et al [37]. Conversely, uremia might lead to
changing patterns of bone-stimulating cytokines anddent risk factors for ABD.
First, diabetes [10, 11] and older age [10, 11, 13, 34] are growth factors, the exact role of which, in any type of
ROD, remains to be further elucidated [24].both described as risk factors for ABD. The suppressive
effect of both factors on osteoblastic function is docu- The anti-proliferative effect of aluminum on the osteo-
blast has been documented [38]. In analogy with themented in vitro [35, 36]. Male gender was recently
described as a predisposing factor for ABD in CAPD increased susceptibility of parathyroid cells to aluminum
when their transferrin receptors are up-regulated [21], anpatients [17]. It has been suggested that the post-meno-
pausal state, with its known increased bone turnover, effect of low level aluminum exposure of osteoblasts—in
cases in which their transferrin receptors are up-regu-confers a protective effect.
A decreasing prevalence of ABD as length of time on lated—can be hypothesized, but it remains to be ex-
plored. The role of a higher calcium exposure on osteo-dialysis increases has been described [11], as well as an
improving response of bone to PTH [14]. Accumulation blast functioning also remains to be further examined.
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Table 2. Causes of osteomalacia known (Table 2). The notion that in these patients
1,25(OH)2 vitamin D3 levels are low and that supraphysi-Aluminum intoxication
Vitamin D deficiency ologic doses of precursormin D are needed to reverse
Severe acidosis the abnormality have led to the concept that calcitriolHypocalcemia
must be the sole active vitamin D metabolite [41, 44].Hypophosphoremia
Fluorosis However, recent data showed distinctly lowered 25(OH)
Strontium vitamin D3 levels in the presence of unaffected calcitriol• • • •
concentrations in patients with osteomalacic lesions as
assessed radiologically by the presence of Looser’s zones.
This finding made Ghazalli et al [41] suggest that 25(OH)
vitamin D3 must also be considered a major risk factorFinally, vitamin D deserves special attention. It has been
for a defective mineralization, hereby acting via a mecha-demonstrated that vitamin D treatment can induce ABD
nism completely independent of calcitriol. In line withwithout decreasing the PTH level [39, 40]. Different
this finding is the high incidence of osteomalacia notedmechanisms have been proposed to explain this effect,
in patients with nephrotic syndrome and in which thebut further experimental data to corroborate them are
histologic changes were correlated significantly with di-required [22].
minished 25(OH) vitamin D3 levels [42].
Osteomalacia has also been associated with metabolic
OSTEOMALACIA acidosis [45]. The mechanism by which this acid-base
disorder affects bone metabolism is not yet fully under-Compared to adynamic bone disease, osteomalacia
has now become a much rarer disease (around 4%), at stood. A direct effect of metabolic acidosis on both osteo-
blastic and osteoclastic activity [46, 47], as well as anleast in Western countries [11]. On the other hand, data
of recent studies indicate that this particular bone disease inhibitory role on the calcification process by decreasing
the proportion of trivalent phosphate essential for miner-entity might still regularly be observed in less developed
countries [41–43]. alization, has been postulated [48]. Aside from acidosis,
many other mineral abnormalities, such as phosphateAlthough in adynamic bone disease osteoblastic activ-
ity is primarily suppressed, osteomalacia originates from depletion or hypophosphatemia, and hypocalcemia or
the Fanconi syndrome [44, 49], play a role in the develop-a direct effect on the mineralization process. With this
type of renal bone disease, the effects of secondary hy- ment of a defective mineralization.
Until a decade ago, osteomalacia in end-stage renalperparathyroidism on bone are overridden by a number
of metabolic abnormalities that finally result in a defec- disease (ESRD) patients mainly resulted from aluminum
exposure, which is known to inhibit bone mineralizationtive bone mineralization, i.e., the lag time between oste-
oid deposition and its mineralization is increased. Histo- by a mechanism that is still poorly understood [50]. In
osteomalacic patients, specific stains for aluminum [51]logically, this results in an increased volume (area) of
lamellar osteoid resulting from widened osteoid seams together with microanalytical techniques [52] have dem-
onstrated the element to be present at the osteoid calcifiedand an increase in the fraction of trabecular surface cov-
ered by osteoid. Often, the irregular interface between bone boundary. With the introduction of aluminum-free
phosphate binders and efficient procedures for waterosteoid and mineralized bone reflecting previously en-
hanced resorbing activity, is in striking contrast to the treatment, the incidence of aluminum-related osteoma-
lacia has dropped dramatically. This type of renal bonesmooth contour of the osteoid–marrow interface. Cellu-
lar activity is low and there is absence or paucity of disease is rarely seen in the current dialysis population
[11]. Toxic inhibition of mineralization has also beenosteoblasts and osteoclasts. Remaining osteoblasts how-
ever, continue to produce osteoid which does not get reported for fluoride [53]. However, the extent to which
this might pose a clinical problem in dialysis patients ismineralized. The abnormal mineralization is evidenced
by a decrease in fraction of trabecular surface exhibiting not clearly understood.
In a recent, world-wide, multicenter study, we deter-tetracycline labels. This decrease comprises less single
labels and a disproportional greater reduction in double mined a number of relevant trace metals in 100 bone
biopsies of dialysis patients with known bone histology.labels. Patients suffer from bone deformities, bone pain
and fractures [4, 44]. Here, it was found that bone strontium levels were in-
creased in patients with osteomalacia as compared to all
Causes of osteomalacia other types of renal osteodystrophy, i.e., mild hyperpara-
thyroidism, osteitis fibrosa, adynamic bone, and mixedThe relationship between exogenous (e.g., nutritional)
and endogenous (moderate/end-stage renal failure, ne- lesion osteodystrophy [abstract: J Am Soc Nephrol 6:935,
1995]. At that time, it was not clear whether in the devel-phrotic syndrome) vitamin D deficiency and the histo-
logic finding of osteomalacia in uremic patients is well opment of osteomalacia strontium either played a pri-
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could be presented experimentally, by adding strontium
to the drinking water of a chronic renal failure rat model
[56]. A direct effect of strontium on bone mineralization
is suggested from the element’s localization in bone.
Indeed, strontium could be localized in calcified bone
by both histochemistry and electron probe microanalysis,
mainly in new bone close to the osteoid/calcification
front, a critical site for bone mineralization. Preliminary
data from currently ongoing experimental dose-finding
studies also point to a complex dose-dependent effect
of strontium on bone in renal failure. Mineralizing osteo-
blast cultures derived from rat calvaria are presently
used to study the mechanism by which strontium inter-
feres with the bone mineralization process, either di-
rectly or indirectly via its interaction with bone matrix
components, such as osteopontin, bone sialoprotein and
osteocalcin. The possibility that strontium interacts with
the bone metabolism via an indirect pathway, e.g., through
interference with the vitamin D biosynthesis, is currently
checked for by means of 1a25(OH)2 vitamin D3 synthe-
sizing renal cell cultures.
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